Costs of two vancomycin-resistant enterococci outbreaks in an academic hospital

被引:2
|
作者
van der Pol, Simon [1 ,2 ]
Lokate, Mariette [3 ]
Postma, Maarten J. [1 ,2 ,4 ]
Friedrich, Alex W. [3 ,5 ]
机构
[1] Univ Med Ctr Groningen, Dept Hlth Sci, Groningen, Netherlands
[2] Hlth Ecore, Zeist, Netherlands
[3] Univ Med Ctr Groningen, Dept Med Microbiol & Infect Control, Groningen, Netherlands
[4] Univ Groningen, Dept Econ Econometr & Finance, Groningen, Netherlands
[5] Univ Hosp Munster, Inst European Prevent Networks Infect Control, Munster, Germany
关键词
VRE;
D O I
10.1017/ash.2022.365
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: In early 2017, the University Medical Center Groningen, the Netherlands, had an outbreak of 2 strains of vancomycin-resistant enterococci (VRE) that spread to various wards. In the summer of 2018, the hospital was again hit by a VRE outbreak, which was detected and controlled early. However, during both outbreaks, fewer patients were admitted to the hospital and various costs were incurred. We quantified the costs of the 2017 and 2018 VRE outbreaks.Design: Using data from various sources in the hospital and interviews, we identified and quantified the costs of the 2 outbreaks, resulting from tests, closed beds (opportunity costs), cleaning, additional personnel, and patient isolation.Setting: The University Medical Center Groningen, an academic hospital in the Netherlands.Results: The total costs associated with the 2017 outbreak were estimated to be <euro>335,278 (US $356,826); the total costs associated with the 2018 outbreak were estimated at <euro>149,025 (US $158,602).Conclusions: The main drivers of the costs were the opportunity costs due to the reduction in admitted patients, testing costs, and cleaning costs. Although the second outbreak was considerably shorter, the costs per day were similar to those of the first outbreak. Major investments are associated with the VRE control measures, and an outbreak of VRE can lead to considerable costs for a hospital. Aggressively screening and isolating patients who may be involved in an outbreak of VRE may reduce the overall costs and improve the continuity of care within the hospital.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Vancomycin-resistant enterococci in vegetarians
    vandenBraak, N
    Kreft, D
    vanBelkum, A
    Verbrugh, H
    Endtz, H
    LANCET, 1997, 350 (9071): : 146 - 147
  • [32] Detection of vancomycin-resistant enterococci
    Mori, S
    JOURNAL OF THE FOOD HYGIENIC SOCIETY OF JAPAN, 1999, 40 (04): : J340 - J341
  • [33] Vancomycin-resistant enterococci: Comment
    Rapp, RP
    ANNALS OF PHARMACOTHERAPY, 1996, 30 (12) : 1500 - 1500
  • [34] Approaches to vancomycin-resistant enterococci
    Torres-Viera, C
    Dembry, LM
    CURRENT OPINION IN INFECTIOUS DISEASES, 2004, 17 (06) : 541 - 547
  • [35] Vancomycin-resistant enterococci: A review
    Joshi, N
    Milfred, D
    Caputo, G
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1996, 5 (09) : 528 - 535
  • [36] Vancomycin-resistant enterococci in Austria
    Allerberger, F
    LassFlorl, C
    Dierich, MP
    Hirschl, AM
    Presterl, E
    Haas, G
    Klare, I
    Witte, W
    WIENER KLINISCHE WOCHENSCHRIFT, 1997, 109 (09) : 312 - 320
  • [37] Commentary: Vancomycin-resistant enterococci
    Welton, L
    Zervos, MJ
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1996, 5 (09) : 535 - 537
  • [38] Topic: Vancomycin-resistant enterococci
    Richard B. Roberts
    Journal of Urban Health, 1998, 75 : 512 - 513
  • [39] Resistance in Vancomycin-Resistant Enterococci
    Miller, William R.
    Murray, Barbara E.
    Rice, Louis B.
    Arias, Cesar A.
    INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2020, 34 (04) : 751 - +
  • [40] The epidemiology of vancomycin-resistant enterococci
    Goossens, H
    CURRENT OPINION IN INFECTIOUS DISEASES, 1999, 12 (06) : 537 - 541